Suzhou Hengrui-Callie Pharmaceutical

Suzhou Hengrui-Callie Pharmaceutical is a specialized biotechnology company focused on the development of innovative metabolic and endocrine therapies. A subsidiary of the major Chinese pharmaceutical firm Jiangsu Hengrui Medicine, the company leverages advanced research in incretin-based therapies to address global health challenges such as type 2 diabetes and obesity. Its lead programs include multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors. The company operates primarily out of the Suzhou Industrial Park, integrating R&D with the broader manufacturing and commercial infrastructure of its parent organization.